<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871256</url>
  </required_header>
  <id_info>
    <org_study_id>AR/STP-UDC</org_study_id>
    <nct_id>NCT04871256</nct_id>
  </id_info>
  <brief_title>Effects of Septorhinoplasty on Allergic Rhinitis</brief_title>
  <official_title>Effects of Septorhinoplasty on Allergic Rhinitis Evolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Pérez Sayáns</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade da Coruña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Santiago de Compostela</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis (AR) is a chronic inflammatory disease that affects almost 30% of adult&#xD;
      population. Some patients associate septal deviation, main cause of chronic nasal&#xD;
      obstruction, and AR. Current literature about AR treatment with septoplasty (STP) is still&#xD;
      contradictory, because is thought that patients with AR are not able to appreciate&#xD;
      improvement after surgery.&#xD;
&#xD;
      Patients diagnosed with allergic rinitis and septal deviation were evaluated to determined&#xD;
      life quality and airflow obstruction evolution after STP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective quasi experimental study. After being informed about the study,&#xD;
      patients that signed written informed consent were included in the study. In week 0 before&#xD;
      surgery, all measurements and questionnaires were performed. 1 month after surgery,&#xD;
      measurements were repeated.&#xD;
&#xD;
      After screening, patient´s obstruction was evaluated by anterior rhinomanometry (RNMa), and&#xD;
      quality of life scored through ESPRINT scale. ESPRINT is a validated Spanish questionnaire&#xD;
      about daily life activity, sleep, psycology and perception of affection by allergic rhinitis.&#xD;
      Symtoms were evaluated with visual analogue scale (VAS) and clinical history. Symptoms like&#xD;
      sneezing, itchy nose, ocular symptoms and/or nasal obstruction. Also medication (intranasal&#xD;
      corticosteroid, antileucotrienos, antihistamines eye drops , antishistamines) frequency use&#xD;
      was registered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A prospective study with 1 months period follow up. Patients with septal deviation and allergic rhinitis diagnosis will be included. Obstruction airflow will be evaluated before and after surgery with rhinomanometry (RNM). Life quality will be assessed with VAS and ESPRINTquestionnaires.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of Airflow rate</measure>
    <time_frame>Change from baseline airflow rate (Before treatment) at 1 month after surgery</time_frame>
    <description>Rhinomanometre will be used to determine airflow rate changes before surgery (septoplasty) and after it. Rhinomanometre will determine airflow rate in cm3/s and also use a quality scale as normal, mild, severe and very severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of symptoms</measure>
    <time_frame>Changes from baseline (Before treatment) at 1 month after surgery</time_frame>
    <description>VAS score. VAS: visual analogue scale. Patients determine their symptoms with a visual scale that range from 0-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in quality of life</measure>
    <time_frame>Changes from baseline (Before treatment) at 1 month after surgery</time_frame>
    <description>ESPRINT questionnaire. This is a validated spanish questionnaire about daily life impairments with 28 items.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Inver</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: after screening, patient´s obstruction will be evaluated by anterior rhinomanometry (RNMa), and quality of life wil be scored through ESPRINT scale. ESPRINT is a validated Spanish questionnaire about daily life activity, sleep, psychology and perception of affection by allergic rhinitis.&#xD;
Symptoms will be evaluated with visual analogue scale (VAS) and clinical history. Symptoms like sneezing, itchy nose, ocular symptoms and/or nasal obstruction. Also medication (intranasal corticosteroid, antileukotrienes, antihistamine eye drops, antihistamine) frequency use will be registered</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Septorhinoplasty</intervention_name>
    <description>This intervention will be performed by the same surgeon, after signing of patient inform consent.</description>
    <arm_group_label>Inver</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Allergic Rhinitis&#xD;
&#xD;
          -  Diagnosis of nasal obstruction with septal deviation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous nasal surgery&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Malignant tumors&#xD;
&#xD;
          -  Severe hepatopathy&#xD;
&#xD;
          -  Obstructive sleep apnea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mario Pérez Sayáns</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15785</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Santiago de Compostela</investigator_affiliation>
    <investigator_full_name>Mario Pérez Sayáns</investigator_full_name>
    <investigator_title>Proffessor</investigator_title>
  </responsible_party>
  <keyword>Septoplasty</keyword>
  <keyword>VAS</keyword>
  <keyword>quality of life</keyword>
  <keyword>allergic rhinitis</keyword>
  <keyword>nasal obstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Results will be shared by articles publication.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT04871256/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

